Brazil Retail Pharmacy Market, By Product (Prescription, OTC), By Type (Chain, Independent, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Market Overview

The Brazil Retail Pharmacy Market size accounted for USD 31.08 Billion in 2025 and is predicted to increase from USD 32.13 Billion in 2026 to approximately USD 49.07 Billion by 2031, expanding at a CAGR of 7.91% from 2026 to 2031.

Key Takeaways

• By product type, the Prescription segment accounted for the largest market share of approximately 68% in 2025, owing to the recurring demand for physician-prescribed medicines, increasing chronic disease management, and the broad range of therapeutic treatments dispensed through retail pharmacies.
• By type of pharmacy, the Chain segment held the largest market share of approximately 54% in 2025, supported by extensive store networks, centralized procurement, competitive pricing, strong brand recognition, standardized services, and greater investment in digital and omnichannel capabilities.
• By region, the South-East region accounted for the largest market share of approximately 54% in 2025, supported by its large urban consumer base, developed healthcare infrastructure, higher concentration of organized pharmacy chains, strong distribution networks, and relatively higher healthcare spending.
• The Central-West region is expected to register the fastest growth, driven by expanding urban centers, improving healthcare infrastructure, increasing retail pharmacy penetration, rising purchasing capacity, and opportunities for organized pharmacy chains to expand into comparatively underserved markets.
• Aging demographics, increasing chronic disease management, growing adoption of generic medicines, expansion of pharmacy-based healthcare services, digitalization of prescription and purchasing processes, and increasing consumer demand for convenient healthcare access are expected to support the long-term growth of the Brazil Retail Pharmacy Market.

Market Drivers

Aging Population and Rising Chronic Disease Burden

Brazil’s aging population and growing prevalence of chronic diseases are increasing demand for prescription medicines, refills, and long-term disease-management products, supporting sustained retail pharmacy revenues. According to the Brazilian Institute of Geography and Statistics (IBGE), people aged 60 years and over accounted for 16.6% of Brazil’s population in 2025, up from 11.3% in 2012. The chronic disease burden further reinforces this demand: Brazil’s Ministry of Health reports that 388 people die from hypertension-related causes each day, while Vigitel continues to monitor hypertension and diabetes prevalence across the country’s capitals. Consequently, retail pharmacies are benefiting from recurring medication needs and increasing demand for accessible chronic-care support.

Increasing Demand for Generic Medicines

Growing consumer adoption of generic medicines is a significant growth driver for Brazil’s retail pharmacy market, supported by their affordability and expanding use in chronic-disease treatment. According to PróGenéricos, Brazil sold 2.36 billion generic medicine units in 2025, representing an 8.33% increase from 2024. Generic medicines also accounted for approximately 76% of unit sales of antihypertensive medicines and 87% of cholesterol-control medicines, highlighting their importance in recurring prescription demand. In addition, Abrafarma reported that generic-medicine revenues across its 29 member pharmacy chains increased 21.8% to R$13.96 billion between November 2024 and October 2025. This combination of affordability, consumer acceptance, and strong chronic-care demand is supporting sustained pharmacy sales.

Expansion of Pharmacy-Based Healthcare Services

Brazilian pharmacies are increasingly evolving from medicine-dispensing outlets into accessible healthcare hubs, supported by demand for testing, vaccination, screening, and pharmaceutical-care services. In 2025, major pharmacy networks conducted approximately 10 million clinical services and recorded 6.8 million patient visits across around 1,500 municipalities. The momentum continued in early 2026, with an estimated 40,000 procedures per day during the first quarter. The networks also operated 9,248 clinical rooms, while vaccination doses increased by 56%. Regulatory developments are further supporting this expansion, with Anvisa’s RDC 978/2025 establishing updated requirements for clinical laboratory testing services, including those offered by pharmacies.

Download Free Sample Report

Market Restraints

High Tax Burden on Medicines

The relatively high tax burden on medicines has historically constrained affordability and increased cost pressure across Brazil’s retail pharmacy sector. A study published in Saúde em Debate estimates that taxes represented approximately 33.1% of the final selling price of medicines, reflecting the combined impact of ICMS, IPI, PIS/Pasep, and Cofins. Although Brazil’s ongoing tax reform is expected to reduce the burden on medicines, the transition is creating additional compliance and pricing complexity for retailers. Under Complementary Law No. 214/2025, IBS and CBS rates on registered medicines are reduced by 60%, while selected medicines qualify for zero rates. Nevertheless, implementation costs and evolving tax rules may continue to pressure pharmacy margins in the near term.

Intense Competition and Consolidation

Intensifying competition and market consolidation are creating significant pressure on smaller and independent pharmacies in Brazil. Large pharmacy chains benefit from greater purchasing power, broader store networks, sophisticated loyalty programs, digital platforms, and stronger logistics capabilities, enabling them to compete more effectively on price and convenience. In 2024, large pharmacy chains represented approximately 47% of Brazil’s retail pharmacy revenue despite accounting for only around 12% of pharmacy establishments. This concentration has continued, with the 29 major Abrafarma networks generating R$114.87 billion in revenue during November 2024–October 2025, up 13.82% year-on-year. Consequently, independent operators face increasing pressure to invest in technology, expand services, strengthen purchasing efficiency, and adopt omnichannel strategies to remain competitive.

Stringent Price Regulation and Margin Pressure

Brazil’s retail pharmacy market faces margin pressure from the country’s regulated medicine-pricing framework. The Chamber of Regulation of the Medicine Market (CMED) establishes the Maximum Consumer Price (PMC), which pharmacies and drugstores cannot exceed, limiting retailers’ pricing flexibility. For the April 2026–March 2027 adjustment cycle, permitted medicine-price increases were capped at 3.81% for Level 1, 2.47% for Level 2, and 1.13% for Level 3. These controlled adjustments can restrict retailers’ ability to fully pass through increases in labor, logistics, utilities, and other operating expenses. Moreover, intense price competition and discounting below the regulated ceiling can further compress margins, particularly for smaller and independent pharmacies.

Market Opportunities

Expansion Through the Farmácia Popular Program

The expansion of Brazil’s Farmácia Popular program creates an opportunity for retail pharmacies to increase their presence in underserved municipalities and strengthen relationships with public-health consumers. As of 2026, the Ministry of Health continues to accept applications from pharmacies in municipalities without participating establishments, with priority given to higher-vulnerability locations. The program covered 4,758 municipalities and 31,170 accredited pharmacies in 2024, benefiting more than 24 million people. Retailers can leverage participation to expand geographic reach, improve store utilization, and build recurring prescription volumes.

Geographic Expansion into Underserved Markets

Brazil’s substantial geographic and healthcare-access disparities provide opportunities for pharmacy operators to expand into smaller cities and underserved regions. The Farmácia Popular expansion illustrates this potential: 444 municipalities gained participating pharmacies between 2023 and 2024, with 94% located in the North and Northeast regions, providing medicine access to more than 230,000 additional people. Retailers capable of adapting store formats, product assortments, and distribution models to smaller markets can capture demand in locations with comparatively limited organized pharmacy coverage.

Partnerships With Healthcare and Technology Ecosystems

Pharmacy operators can pursue partnerships with healthcare providers, technology companies, insurers, employers, laboratories, and digital-health platforms to create integrated consumer journeys. Potential applications include digital health referrals, medication-adherence programs, remote consultations, health-data platforms, and employer wellness initiatives. With organized pharmacy networks already reaching more than 1,100 municipalities and thousands of stores equipped for examinations and vaccination, the physical infrastructure provides a platform for broader healthcare partnerships. Such collaborations could create new revenue streams while strengthening pharmacies’ position within Brazil’s wider healthcare ecosystem.

Market Trends

Omnichannel Retailing and Unified Customer Journeys

Brazil’s pharmacy sector is increasingly adopting an omnichannel model that integrates physical stores, websites, mobile applications, digital prescriptions, and delivery services. Rather than treating online and offline channels separately, retailers are connecting inventory, customer accounts, promotions, and purchasing journeys across platforms. Digital sales among the 29 Abrafarma member networks reached R$21.58 billion between December 2024 and November 2025, up 54.82% year-on-year, indicating a substantial shift in purchasing behavior. The trend is moving beyond simple e-commerce toward integrated retail ecosystems, where customers can search online, verify availability, purchase digitally, and receive products through home delivery or collect them at stores.

Digitalization of Prescription Management

The sector is moving toward greater use of electronic prescription and centralized prescription-management systems. In 2026, Anvisa began integrating electronic-prescription platforms with the Sistema Nacional de Controle de Receituários (SNCR), enabling greater traceability from prescription issuance through dispensing. The system is designed to reduce fraud, prevent prescription reuse, and standardize controlled-medicine management nationally. This transition is encouraging pharmacies to upgrade their information systems and establish stronger connectivity with prescribers and healthcare platforms.

Emergence of New High-Demand Therapeutic Categories

The pharmacy market is experiencing rapid changes in product mix as newer therapeutic categories gain consumer attention. A prominent example is the sharp rise in demand for GLP-1-based weight-management medicines. Between January and September 2025, online sales of weight-loss injection pens reached 2.34 million units and R$3.01 billion, nearly five times the revenue recorded in the same period of 2024. The trend is influencing product assortment, prescription verification, inventory planning, and consumer education within retail pharmacies.

Market Report Coverage and Key Metrics

Market Segmentation Analysis

By Product Insights

Why Did Prescription Secure the Largest Share of the Brazil Retail Pharmacy Market?

Prescription medicines are estimated to account for approximately 68% of Brazil’s retail pharmacy market by revenue. Their leading position is primarily supported by the recurring nature of prescription-based treatment, particularly for chronic and long-term conditions requiring continuous medication. Prescription products also encompass a broad range of therapeutic categories, including cardiovascular, metabolic, respiratory, neurological, and specialty treatments, creating a diversified revenue base for pharmacies. Physician-directed treatment further supports consistent dispensing volumes and reduces substitution with non-pharmaceutical alternatives. In addition, prescriptions generally involve higher-value purchases than many OTC products, particularly for branded and specialty therapies. The combination of recurring demand, broad therapeutic coverage, treatment continuity, and relatively higher transaction values enables prescription medicines to maintain the largest revenue share.

By Type Insights

Why Did Chain Dominate the Brazil Retail Pharmacy Market?

The Chain segment is estimated to account for approximately 54% of the Brazil Retail Pharmacy Market by revenue. Its dominance is primarily attributable to the economies of scale achieved through centralized procurement, distribution, and inventory management, enabling competitive pricing and broader product availability. Chain pharmacies also benefit from strong brand recognition and standardized operating models, which promote consumer trust and consistent service quality across locations. Their extensive networks provide greater geographic coverage and convenient access to medicines and healthcare products. In addition, chains can invest more effectively in loyalty programs, digital platforms, analytics, and integrated retail systems, strengthening customer retention and purchasing frequency. Their ability to combine purchasing scale, operational efficiency, brand strength, and technological capabilities gives them a sustained advantage over fragmented independent pharmacies.

Download Free Sample Report

Market Regional Analysis: South-East, North-East, South, Central West, North

Why Did South-East Lead the Brazil Retail Pharmacy Market?

The South-East region is estimated to account for approximately 54% of the Brazil Retail Pharmacy Market, supported by its large and highly urbanized consumer base, concentrated across São Paulo, Rio de Janeiro, Minas Gerais, and Espírito Santo. The region benefits from a comparatively developed healthcare ecosystem, including hospitals, physicians, private healthcare providers, and pharmaceutical distribution infrastructure, which supports strong medicine purchasing and dispensing activity. Its dense metropolitan areas also facilitate extensive pharmacy coverage and efficient distribution, enabling retailers to serve high volumes of consumers. In addition, stronger economic activity and purchasing capacity support greater spending on prescription medicines, OTC products, personal care, and wellness categories. The concentration of organized pharmacy chains further reinforces the region’s market leadership.

Why Is Central West Expected to Register the Fastest Growth in the Brazil Retail Pharmacy Market?

The Central-West region is expected to register the fastest growth, supported by expanding urbanization, economic development, and increasing healthcare infrastructure across Brasília, Goiás, Mato Grosso, and Mato Grosso do Sul. The region’s continued development of medium-sized urban centers is creating new healthcare and retail catchment areas, while improvements in healthcare access are encouraging greater utilization of formal pharmacy channels. Growing commercial activity and rising household purchasing capacity are also expected to support greater spending on prescription medicines, OTC products, and health-related goods. In addition, the region’s relatively less-developed pharmacy coverage compared with Brazil’s major southeastern markets provides substantial room for organized retailers to expand. The combination of urban expansion, healthcare-market development, and increasing retail penetration is expected to accelerate pharmacy-market growth.

Key Market Players

• Raia Drogasil
• Grupo DPSP
• Pague Menos
• Drogaria Onofre
• Drogaria Pacheco
• Farmácias Guarulhos

Recent Developments

In August 2026, Anvisa opened a regulatory process to establish rules for pharmacies using e-commerce platforms and digital channels for medicine logistics and delivery, following Law 15.357/2026. The initiative is expected to clarify responsibilities for pharmacies and platforms while maintaining pharmaceutical safety requirements.

In July 2026, Assaí launched its first Assaí Farma store in São Paulo and announced plans to reach 25 pharmacy units by year-end, marking a significant expansion of competition from the food-retail sector into pharmacy retail.

Report Scope:

By Product

• Prescription
• OTC

By Type

• Chain
• Independent
• Others

By Region

• South-East
• North-East
• South
• Central West
• North

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Brazil Retail Pharmacy Market.

Available Customizations:

Brazil Retail Pharmacy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).